Vaccines - Germany

Germany

The Vaccines market in Germany is anticipated to witness substantial growth, with projected revenue reaching €2,589.00m by 2024.
This growth is expected to continue at a steady pace, with an annual growth rate (CAGR 2024-2029) of 4.24%.
This will result in a market volume of €3,186.00m by 2029.
When compared globally, United States is projected to generate the highest revenue in the Vaccines market, with an estimated €27,010.00m in 2024.
Germany is at the forefront of vaccine development, with a strong focus on research and innovation in the field.

Key regions: Australia, Italy, France, South Korea, Brazil

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Vaccines market in Germany has been seeing a positive trend in recent years, with increasing demand for various types of vaccines.

Customer preferences: German consumers have been showing a growing interest in preventative healthcare, leading to an increase in demand for vaccines. In addition, the COVID-19 pandemic has raised awareness about the importance of vaccines, leading to a surge in demand for COVID-19 vaccines in particular.

Trends in the market: One trend in the German Vaccines market is the increasing focus on research and development of new vaccines. Many pharmaceutical companies are investing heavily in R&D to develop new vaccines for a range of diseases. Another trend is the growing popularity of combination vaccines, which offer protection against multiple diseases in a single shot.

Local special circumstances: Germany has a well-established healthcare system, with a high level of public investment in healthcare infrastructure and services. This has created a favorable environment for the development and distribution of vaccines. In addition, the country has a strong tradition of preventative healthcare, which has helped to drive demand for vaccines.

Underlying macroeconomic factors: The German economy has been relatively stable in recent years, with steady GDP growth and low unemployment. This has contributed to a favorable business environment for pharmaceutical companies operating in the Vaccines market. In addition, the German government has been supportive of the healthcare sector, with policies aimed at promoting innovation and investment in healthcare R&D.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.